Artificial Intelligence Could Transform Drug Research for Heart Diseases
A new study highlights the potential of artificial intelligence (AI) to support drug research for heart diseases in a more effective and data-driven manner. The AI model CardioKG, developed in the UK, can analyze thousands of individuals’ heart imaging data—covering both patients and healthy volunteers—alongside extensive clinical databases to predict which drugs could be beneficial in specific conditions.
The research indicates that some existing drugs may unexpectedly provide benefits in heart disease. For instance, the AI model predicts that the anti-inflammatory drug methotrexate could be beneficial for heart failure, while gliptins, a class of diabetes medications, might help patients with heart rhythm disorders. By leveraging AI, researchers can analyze potential effects not only based on genetic data but also considering individual patients’ cardiac function and clinical profiles.
Experts emphasize that this approach could illuminate treatment pathways and enable more precise, data-driven decisions in drug development and research planning. The technology may contribute to the advancement of personalized treatment strategies within healthcare systems and could become a valuable tool in future clinical studies and decision-making processes.